News

Dynavax expects to receive nearly $200m in milestone payments over the term of the alliance. Dynavax and GSK will focus on the development of a TLR8 inhibitor to

XmAb5871, a humanized monoclonal antibody using selective dual-targeting mechanism for B cell inhibition by targeting the antigen CD19 and co-engaging CD32b (Fc?RIIb), helps in suppression of autoimmune response.

DEFINE (Determination of the Efficacy and safety of oral Fumarate IN rElapsing-remitting MS) a global, randomized, double-blind, placebo-controlled, dose-comparison trial enrolled 1,237 patients between 18 and 55 years

ImmuPharma and Cephalon had signed an option agreement in 2008,when the ImmuPharma designed and funded Phase IIb study was ongoing. ImmuPharma was paid $15m by Cephalon before the

Newron will now re-assess all the opportunities for safinamide including re-partnering the compound at some stage. Newron can also pursue marketing of this new chemical entity for Parkinson’s

Modernizing Medicine EMA-Ophthalmology HER featuring a bi-directional communication interface enables a seamless workflow experience across both clinical and financial areas of ophthalmology practice, besides enabling access from anywhere

The chemicals present in bath salts including mephedrone, methylenedioxypyrovalerone (MDPV) and methylone have been banned for around one year for public safety, Reuters reported. A permanent ban on

Onko-Sure blood test kit is a 96-well Enzyme-linked immunosorbent assay (ELISA) which is used to detect and treat 19 different types of cancers. Radient Pharmaceuticals chairman and CEO

MANF is a potent neurotrophic factor which is used to treat apoptosis-related diseases including Parkinson’s disease. Amarantus claims to protect its compositions of matter and methods of use